OCT 12, 2021 5:30 AM PDT

Cancer Drug Helps Alzheimer's Mice Remember

WRITTEN BY: Tara Fernandez

What if a drug—specifically developed to treat one disease—had the potential to address other non-related conditions as well? One of the earliest examples of successful drug repurposing is aspirin. The drug was initially marketed as a painkiller in 1899. Since the early 1980s, however, aspirin has also been widely used to treat cardiovascular conditions. Ongoing research may see aspirin pivot yet again, this time for use in colorectal cancer patients.

Now, neuroscientists on the hunt for therapeutic approaches to treating Alzheimer’s disease have stumbled on an unlikely therapy that’s showing immense promise: a chemotherapy drug. Scientists at the University of British Columbia showed that Axitinib (sold under the brand name Inlyta), could help improve cognitive function and restore memory in animal models of Alzheimer’s. 

Drug development for Alzheimer’s has, until now, had a bleak history of failure. 99.6 percent of Alzheimer’s drugs end up failing at the clinical trial stage, resulting in billions of investment dollars lost. As a result, an estimated 50 million people worldwide live with the neurodegenerative condition, without any effective clinically available preventative or treatment options available.

The results of the new study are cause for hope, said the lead author Wilf Jefferies. “We are really very excited because these findings suggest we can repurpose approved anti-cancer drugs for use as treatments for Alzheimer’s disease.” 

“It could shorten the clinical development by years.”

Axitinib’s mode of action resists tumors by inhibiting the growth of blood vessels in tumors. Cancers secrete chemicals that cause networks of blood vessels to sprout to feed the rapidly dividing malignant cells. Interestingly, this phenomenon is also observed in the brains of Alzheimer’s patients.

The vast majority of (failed) Alzheimer’s drugs work by targeting tau or beta-amyloid proteins in patients. However, Jefferies and colleagues have pioneered the strategy of blocking angiogenesis—the formation of new blood vessels. 

In their study, the researchers detail how one month of Axitinib treatment significantly stopped the growth of blood vessels and healed the blood-brain barrier in a mouse model of Alzheimer’s. These physiological changes were closely associated with cognitive improvements: treated mice remembered how to get around a maze they were trained to navigate to reach a reward.

The study was published in the peer-reviewed journal, The Lancet

 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 18, 2021
Cannabis Sciences
Cannabis Use Disorder Linked to COVID Hospitalization
AUG 18, 2021
Cannabis Use Disorder Linked to COVID Hospitalization
People with a genetic predisposition to cannabis use disorder (CUD) are more likely to require hospitalization after con ...
SEP 21, 2021
Immunology
1 in 5 Hospitalized COVID Patients Develop Self-Destructive Antibodies
SEP 21, 2021
1 in 5 Hospitalized COVID Patients Develop Self-Destructive Antibodies
One in five hospitalized COVID-19 patients go on to develop autoantibodies—immune molecules that mistakenly target ...
SEP 26, 2021
Coronavirus
LIBRA-Seq ID's a Potent Antibody to Fight COVID-19
SEP 26, 2021
LIBRA-Seq ID's a Potent Antibody to Fight COVID-19
Humans can produce millions or even billions of antibodies, so only so many can be captured and screened. But those anti ...
OCT 12, 2021
Immunology
Major Landmark in a 100-Year Search for a Malaria Vaccine
OCT 12, 2021
Major Landmark in a 100-Year Search for a Malaria Vaccine
In one of the greatest global health milestones of our time, the World Health Organization has approved the widespread d ...
OCT 18, 2021
Cancer
The History of Immunotherapy: Toxins, Targets & T Cells
OCT 18, 2021
The History of Immunotherapy: Toxins, Targets & T Cells
Cancer immunotherapy, a treatment that directly enhances a patient’s immune system, is typically perceived as a mo ...
NOV 23, 2021
Immunology
Obesity Drives Inflammation, Puts Teeth at Risk
NOV 23, 2021
Obesity Drives Inflammation, Puts Teeth at Risk
Work by University at Buffalo researchers has identified a link between obesity and gum disease. As gum disease escalate ...
Loading Comments...